» Articles » PMID: 33777321

Fucoxanthin Prevents 6-OHDA-Induced Neurotoxicity by Targeting Keap1

Overview
Publisher Wiley
Date 2021 Mar 29
PMID 33777321
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

As the most abundant marine carotenoid extracted from seaweeds, fucoxanthin (FUC) is considered to have excellent neuroprotective activity. However, the target of FUC for its neuroprotective properties remains largely unclear. Oxidative stress is one of the initiating factors causing neuronal cell loss and necrosis, and it is also an important inducement of Parkinson's disease (PD). In the present study, the neuroprotective effect of FUC was assessed using a 6-hydroxydopamine- (6-OHDA-) induced neurotoxicity model. FUC suppressed 6-OHDA-induced accumulation of intracellular ROS, the disruption of mitochondrial membrane potential, and cell apoptosis through the Nrf2-ARE pathway. Keap1 as a repressor of Nrf2 can regulate the activity of Nrf2. Here, the biolayer interferometry (BLI) assay demonstrated that FUC specifically targeted Keap1 and inhibited the interaction between Keap1 and Nrf2. FUC bound to the hydrophobic region of Keap1 pocket and formed hydrogen bonding interactions with Arg and Tyr. Besides, it also dose-dependently upregulated the expressions of antioxidant enzymes, such as nicotinamide heme oxygenase-1, glutamate-cysteine ligase modifier subunit, and glutamate-cysteine ligase catalytic subunit, in 6-OHDA-induced PC12 cells. In 6-OHDA-exposed zebrafish, FUC pretreatment significantly increased the total swimming distance of zebrafish larvae and improved the granular region of the brain tissue damage. These results suggested that FUC could protect the neuronal cells against 6-OHDA-induced injury via targeting Keap1.

Citing Articles

Mitochondrial protective potential of fucoxanthin in brain disorders.

Ferdous K, Jansen J, Amjad E, Pray E, Bloch R, Benoit A J Nutr Sci. 2025; 13():e21.

PMID: 39776519 PMC: 11704942. DOI: 10.1017/jns.2024.16.


Marine Pharmacology in 2019-2021: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous....

Mayer A, Mayer V, Swanson-Mungerson M, Pierce M, Rodriguez A, Nakamura F Mar Drugs. 2024; 22(7).

PMID: 39057418 PMC: 11278370. DOI: 10.3390/md22070309.


Natural Bioactive Compounds from Macroalgae and Microalgae for the Treatment of Alzheimer's Disease: A Review.

Lee J, Wong C, Koh R, Lim C, Kok Y, Chye S Yale J Biol Med. 2024; 97(2):205-224.

PMID: 38947104 PMC: 11202106. DOI: 10.59249/JNKB9714.


Antioxidant and Neuroprotective Effects of Fucoxanthin and Its Metabolite Fucoxanthinol: A Comparative In Vitro Study.

Pruccoli L, Balducci M, Pagliarani B, Tarozzi A Curr Issues Mol Biol. 2024; 46(6):5984-5998.

PMID: 38921028 PMC: 11202671. DOI: 10.3390/cimb46060357.


The Protection of EGCG Against 6-OHDA-Induced Oxidative Damage by Regulating PPARγ and Nrf2/HO-1 Signaling.

Xu Q, Chen Y, Chen D, Reddy M Nutr Metab Insights. 2024; 17:11786388241253436.

PMID: 38800717 PMC: 11128170. DOI: 10.1177/11786388241253436.


References
1.
Lin J, Yu J, Zhao J, Zhang K, Zheng J, Wang J . Fucoxanthin, a Marine Carotenoid, Attenuates -Amyloid Oligomer-Induced Neurotoxicity Possibly via Regulating the PI3K/Akt and the ERK Pathways in SH-SY5Y Cells. Oxid Med Cell Longev. 2017; 2017:6792543. PMC: 5591933. DOI: 10.1155/2017/6792543. View

2.
Yan W, Lin G, Zhang R, Liang Z, Wu W . Studies on the bioactivities and molecular mechanism of antioxidant peptides by 3D-QSAR, in vitro evaluation and molecular dynamic simulations. Food Funct. 2020; 11(4):3043-3052. DOI: 10.1039/c9fo03018b. View

3.
Londhe A, Gadhe C, Lim S, Pae A . Investigation of Molecular Details of Keap1-Nrf2 Inhibitors Using Molecular Dynamics and Umbrella Sampling Techniques. Molecules. 2019; 24(22). PMC: 6891428. DOI: 10.3390/molecules24224085. View

4.
Zhang Q, Chen S, Yu S, Qin J, Zhang J, Cheng Q . Neuroprotective effects of pyrroloquinoline quinone against rotenone injury in primary cultured midbrain neurons and in a rat model of Parkinson's disease. Neuropharmacology. 2016; 108:238-51. DOI: 10.1016/j.neuropharm.2016.04.025. View

5.
Smeyne M, Smeyne R . Glutathione metabolism and Parkinson's disease. Free Radic Biol Med. 2013; 62:13-25. PMC: 3736736. DOI: 10.1016/j.freeradbiomed.2013.05.001. View